The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.

Andrew J Armstrong,Taro Iguchi,Arun A Azad,Arnauld Villers,Boris Alekseev,Daniel P Petrylak,Russell Z Szmulewitz,Antonio Alcaraz,Neal D Shore,Jeffrey Holzbeierlein,Francisco Gomez-Veiga,Brad Rosbrook,Fabian Zohren,Gabriel P Haas,Georgia Gourgiotti,Nader El-Chaar,Arnulf Stenzl

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用 1|浏览7

暂无评分

摘要

This study considered two treatment options for metastatic hormone-sensitive prostate cancer in patients with one to five metastases or six or more metastases. Treatment with enzalutamide plus ADT improved survival and other outcomes over ADT alone, whether patients had few or many metastases.

查看译文

关键词

Enzalutamide,Metastatic hormone-sensitive prostate cancer,Oligometastatic prostate cancer,Overall survival,Polymetastatic prostate cancer,Radiographic progression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要